Results 61 to 70 of about 39,319 (333)

Novel pyrrolobenzodiazepine benzofused hybrid molecules inhibit NF-κB activity and synergise with bortezomib and ibrutinib in hematological cancers [PDF]

, 2020
Chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) are incurable hematological malignancies that are pathologically linked with aberrant NF-κB activation.
Ashelford, Kevin, Corcoran, David B, Fegan, Christopher D, Giles, Peter J, Lewis, Thomas, Pepper, Andrea G S, Pepper, Christopher, Rahman, Khondaker Miraz, Thurston, David E, Walsby, Elisabeth J   +9 more
core   +4 more sources

Cardiovascular Magnetic Resonance Imaging in Patients With Ibrutinib-Associated Cardiotoxicity.

JAMA Oncology, 2023
Importance Ibrutinib has been associated with serious cardiotoxic arrhythmias. In preclinical models, these events are paralleled or proceeded by diffuse myocardial injury (inflammation and fibrosis).
B. Buck, Aaron P Chum, Mitkumar Patel, R. Carter, Haseeb Nawaz, V. Yildiz, P. Ruz, Tracy E. Wiczer, K. Rogers, F. Awan, S. Bhat, A. Guha, A. Kittai, O. Simonetti, S. Raman, Grant M. Wallace, Reynaldo Sanchez, Janice M. Bonsu, J. Gambril, D. Haddad, James Mann, Lai Wei, Onaopepo O. Kola-Kehinde, J. Byrd, J. Woyach, D. Addison   +25 more
semanticscholar   +1 more source

Drug Monographs: Ibrutinib and Ramucirumab [PDF]

Hospital Pharmacy, 2014
The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Dominic A. Solimando, James Waddell
openaire   +3 more sources

Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages [PDF]

, 2015
We have read with great interest the recent article of Kohrt, H.E. et al1 showing that Ibrutinib prevented NK cell mediated cytotoxicity of antibody-coated CLL cells in vitro.
Almejún, María Belén, Bezares, Raimundo F., Borge, Mercedes, Cabrejo, María, Colado, Ana, Fernández Grecco, Horacio, Gamberale, Romina, Giordano, Mirta Nilda, Podaza, Enrique Arturo   +8 more
core   +2 more sources

Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia

Clinical Cancer Research, 2023
Purpose: The CAPTIVATE study investigated first-line ibrutinib plus venetoclax for chronic lymphocytic leukemia in 2 cohorts: minimal residual disease (MRD)-guided randomized discontinuation (MRD cohort) and Fixed Duration (FD cohort). We report outcomes
J. Allan, I. Flinn, T. Siddiqi, P. Ghia, C. Tam, T. Kipps, P. Barr, Anna Elinder Camburn, A. Tedeschi, X. Badoux, R. Jacobs, B. Kuss, L. Trentin, Cathy Zhou, A. Szoke, C. Abbazio, W. Wierda   +16 more
semanticscholar   +1 more source

Ibrutinib: coming of age? [PDF]

Blood, 2018
In this issue of Blood, O’Brien et al report long-term efficacy and safety of ibrutinib in the first cohort of patients with chronic lymphocytic leukemia (CLL) treated, now with 5-year follow-up, the longest of any CLL cohort to date ...
openaire   +3 more sources

Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma

Haematologica, 2022
Mantle cell lymphoma (MCL) is an incurable B-cell non-Hodgkin lymphoma characterized by frequent relapses. The development of resistance to ibrutinib therapy remains a major challenge in MCL.
Lingzhi Li, Lei Nie, Alexa Jordan, Qingsong Cai, Yang Liu, Yijing Li, Yuxuan Che, Jovanny Vargas, Zhihong Chen, Angela Leeming, Wei Wang, Yixin Yao, Michael Wang, Vivian Changying Jiang   +13 more
doaj   +1 more source

A Phase I/II first-line study of R-CHOP plus B-cell receptor/NF-κB-double-targeting to molecularly assess therapy response [PDF]

, 2019
The ImbruVeRCHOP trial is an investigator-initiated, multicenter, single-arm, open label Phase I/II study for patients 61-80 years of age with newly diagnosed CD20+ diffuse large B-cell lymphoma and a higher risk profile (International Prognostic Index ...
Anagnostopoulos, Ioannis, Bittner, Aitomi, Denker, Sophy, Frick, Mareike, Hummel, Michael, Kase, Julia, Na, Il-Kang, Schmitt, Clemens A.   +7 more
core   +2 more sources

Second-generation inhibitors of Bruton tyrosine kinase

Journal of Hematology & Oncology, 2016
Bruton tyrosine kinase (BTK) is a critical effector molecule for B cell development and plays a major role in lymphoma genesis. Ibrutinib is the first-generation BTK inhibitor.
Jingjing Wu, Christina Liu, Stella T. Tsui, Delong Liu   +3 more
doaj   +1 more source

Is a Malleable Active Site Loop the Key to High Substrate Promiscuity? Hybrid, Biocatalytic Route to Structurally Diverse Taxoid Side Chains with Remarkable Dual Stereocontrol

Angewandte Chemie, EarlyView.
A highly stereoselective, dynamic reductive kinetic resolution (DYRKR) entry into myriad Taxotere‐like side chains with Clostridium acetobutylicum alcohol dehydrogenase (CaADH) enzyme is reported. Follow‐on cross couplings expand the structural diversity of the library (36 total examples).
Gaurav P. Kudalkar, Florian Leidner, Nivesh Kumar, Jared L. Hass, Peter Madzelan, Douglas R. Powell, Victor W. Day, Pierre Le Magueres, Joseph D. Ferrara, Lee M. Daniels, Akihito Yamano, Sho Ito, Wei Niu, Helmut Grubmüller, Mark A. Wilson, David B. Berkowitz   +15 more
wiley   +2 more sources